Unlocking Personalized Treatment Through Next-Generation Sequencing (NGS)
What Is Next-Generation Sequencing (NGS)?
Next-Generation Sequencing (NGS) is an advanced form of molecular testing that analyzes the genetic makeup of a tumor. By identifying biomarkers, mutations, and gene fusions that may be driving tumor growth, NGS provides a more complete understanding of each patient's unique disease.
No two brain tumors are exactly alike. NGS can help physicians make more informed treatment decisions, identify patients who may be eligible for targeted therapies, and uncover clinical trial opportunities based on a tumor's specific molecular profile. As precision medicine continues to advance, NGS is becoming an increasingly important tool for helping patients explore personalized treatment options that may not have otherwise been considered.
A Historic Milestone in Diffuse Midline Glioma Treatment
In a historic milestone for the diffuse midline glioma (DMG) community, the U.S. Food and Drug Administration (FDA) approved Modeyso™ (dordaviprone) as the first and only FDA-approved treatment for recurrent H3 K27M-mutant diffuse midline glioma. This ultra-rare and aggressive brain tumor primarily affects children and young adults and has long lacked effective treatment options. The approval marks a significant advancement for patients and families facing this devastating diagnosis.
The approval was based on clinical data demonstrating meaningful and durable responses in patients with recurrent disease, offering new hope where few options previously existed. While continued research remains critical, this milestone represents an important step forward in improving outcomes and expanding treatment possibilities for individuals living with DMG.
The End Brain Cancer Initiative will be hosting an internal Patient and Healthcare Professional insights Diffuse Midline Glioma (DMG) Roundtable on August 26th, 2026 @11AM featuring leading experts, researchers, advocates, and members of the patient community to discuss the latest treatment advances, clinical trials, and emerging research.
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), their purpose is to innovate to transform the lives of patients and their families.
They are dedicated to developing life-changing medicines for people with rare diseases — often with limited or no therapeutic options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
They have a diverse portfolio of marketed medicines, including leading therapies addressing rare epilepsies, cancers and sleep disorders. Their patient-focused and science-driven approach powers pioneering research and development advancements across their robust pipeline of innovative therapeutics.
ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND
Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.
